Calcumin (Curcumin)
PreclinicalSmall molecule
Calcumin (Curcumin) is one of 29 small molecule programs targeting Familial adenomatous polyposis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Familial Adenomatous Polyposis
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Actigall
AbbVieApproved
E-Mycin
AAzurity Pharmaceuticals
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Phase 3
Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 3
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Phase 3
Tums
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calcumin (Curcumin). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Puerto Rico